Epitalon Side Effects: A Russian Anti-Aging Tetrapeptide Without Western Approval
Epitalon is a tetrapeptide (Ala-Glu-Asp-Gly) developed at the Saint Petersburg Institute of Bioregulation and Gerontology. It is marketed as an anti-aging peptide claiming effects on telomerase and pineal function. It is not FDA-, EMA-, or TGA-approved.
Epitalon is not FDA-approved and lacks controlled human safety data. Not FDA-, EMA-, or TGA-approved. Most published clinical research is from Russian sources and has not been replicated under Western regulator standards. This page summarises the published literature and regulator positions. It is not medical advice.
Key Takeaways
- Epitalon is a Russian tetrapeptide marketed as an anti-aging compound.
- Not FDA-approved. Not EMA-approved. Not TGA-approved.
- Most published clinical research comes from Russian sources and is not characterised by Western regulators.
- Marketing claims around telomerase and longevity exceed the strength of regulator-reviewed human evidence.
- Compounded or online Epitalon is not pharmaceutical-grade.
What is Epitalon, and what is it marketed for?
Epitalon (tetrapeptide AEDG). Russian-language and translated literature describe Epitalon as a tetrapeptide that influences telomerase expression, pineal melatonin secretion, and gerontological measures. Replication under Western regulator-reviewed conditions is limited.
What side effects and safety concerns have been reported?
The summary below draws from the published literature and regulator statements. Severity classification follows the source documents.
| Concern | What has been reported | Source |
|---|---|---|
| No Western regulator review | Not evaluated by FDA, EMA, or TGA | Approval and most published evidence are limited to the Russian Federation |
| Telomerase claim | Marketing emphasises telomerase effects, but human data supporting longevity claims are limited | Published claims exceed regulator-reviewed evidence |
| Long-term safety | Long-term human safety data outside Russia are absent | Limited Western surveillance |
| Injection infection (compounded) | Pain, abscess, sepsis from non-sterile product | Compounded peptide quality is variable |
Taking Epitalon alongside prescription medicines?
Allmeds scans interactions across your full medication list. Free for individuals.
Common Questions About Epitalon
No. Epitalon is not approved by the FDA, EMA, or TGA. It is not a regulator-supported therapeutic in Western markets.
Russian publications describe gerontological effects in animal and human studies. These claims have not been replicated under Western regulator review and are not endorsed by the FDA, EMA, or TGA.
Because there is limited Western safety data, side effects are not well characterised. Theoretical concerns include immunogenicity, impurities in compounded product, infection from non-sterile injection, and uncharacterised effects on hormone axes.
Compounded or research-grade Epitalon is not pharmaceutical-grade. Purity, potency, and sterility are not guaranteed.
References
- Khavinson VKh et al. Peptide regulation of aging: 35-year research experience. Bull Exp Biol Med. 2014. Source.
- Anisimov VN et al. Effect of Epithalon on biomarkers of aging. Mech Ageing Dev. 2003. Source.
- U.S. Food & Drug Administration. FDA position on bulk drug substances for compounding. Source.